Molecular pathogenesis of the antiphospholipid syndrome

Circulation Research

Volumn 90, Issue 1, 2002, Pages 29-37

  Rand, Jacob H ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Annexins; Anticardiolipin antibodies; Antiphospholipid antibodies; Lupus anticoagulants; Thrombosis

Indexed keywords

ANTITHROMBIN III; BETA2 GLYCOPROTEIN 1; ICOSANOID; LIPOCORTIN 5; PHOSPHOLIPID; PHOSPHOLIPID ANTIBODY; PHOSPHOLIPID BINDING PROTEIN; PROTEIN C; THROMBOPLASTIN;

ANTIBODY BLOOD LEVEL; ANTIGEN SPECIFICITY; ANTIPHOSPHOLIPID SYNDROME; AUTOIMMUNE DISEASE; ENZYME ACTIVITY; HUMAN; ICOSANOID METABOLISM; LEUKOCYTE; NONHUMAN; PATHOGENESIS; PATHOPHYSIOLOGY; PHOSPHOLIPID MEMBRANE; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; THROMBOCYTE; THROMBOSIS; VASCULAR ENDOTHELIUM;

ANIMALS; ANNEXIN A5; ANTIBODIES, ANTIPHOSPHOLIPID; ANTIPHOSPHOLIPID SYNDROME; BETA 2-GLYCOPROTEIN I; BLOOD COAGULATION FACTORS; GLYCOPROTEINS; HUMANS; MODELS, BIOLOGICAL;

EID: 0037059463     PISSN: 00097330     EISSN: None     Source Type: Journal    
DOI: 10.1161/hh0102.102795     Document Type: Review

References (110)

1. The antiphospholipid syndrome
2. Papers and abstracts from the 9th international symposium on antiphospholipid antibodies. Tours, France, September 12-16, 2000
3. The anticardiolipin syndrome
4. Antiphospholipid antibodies: An elderly statesman dons new garments
5. Biologically false positive serological tests for syphilis: Type, incidence, and cause
6. Natural history of systemic lupus erythematosus: Approach to its study through chronic biologic false positive reactors
7. Lupus anticoagulants
8. A brain extract as a substitute for platelet suspensions in the thromboplastin generation test
9. A hemorrhagic disorder caused by circulating anticoagulant in patients with disseminated lupus erythematosus
10. Acquired inhibitors of blood coagulation
11. Thrombosis in systemic erythematosus despite circulating anticoagulants
12. Hypergammaglobulinemia, circulating anticoagulant and biologic false-positive Wassermann reaction
13. Anticardiolipin antibodies: Detection by radio-immunoassay and association with thrombosis in systemic lupus erythematosus
14. 2 glycoprotein I and anticardiolipin antibodies in leptospirosis, syphilis and Kala-azar
15. Seasonal distribution of antiphospholipid antibodies
16. Familial lupus anticoagulant. A case report and review of the literature
17. The immunogenetics of the antiphospholipid syndrome, anticardiolipin antibodies, and lupus anticoagulant
18. MHC studies of the primary antiphospholipid antibody syndrome and of antiphospholipid antibodies in systemic lupus erythematosus
19. Relationship of anticardiolipin antibodies and antiphospholipid syndrome to HLA-DR7 in Mexican patients with systemic lupus erythematosus (SLE)
20. Genetic risk factors for aPL syndrome
21. 2-glycoprotein I
22. New Orleans 7th international symposium on antiphospholipid antibodies. Proceedings and abstracts
23. Antiphospholipid antibodies: Basic immunology and assays
24. Autoantibodies to phospholipid-binding plasma proteins in patients with thrombosis and phospholipid-reactive antibodies
25. 2-glycoprotein I antibodies from autoantibody and immunized sources
26. 2-glycoprotein I
27. 2-glycoprotein I to phospholipids based on its crystal structure
28. 2-glycoprotein I: Implications for phospholipid binding and the antiphospholipid syndrome
29. 2 glycoprotein I complexes to lipid membranes
30. 2 Glycoprotein I is a major protein associated with very rapidly cleared liposomes in vivo, suggesting a significant role in the immune clearance of "non-self" particles
31. Apoptotic cell clearance in systemic lupus erythematosus, I: Opsonization by antiphospholipid antibodies
32. 2 glycoprotein I of human serum
33. 2-Glycoprotein I deficiency: Prevalence, genetic background and effects on plasma lipoprotein metabolism and hemostasis
34. 2-Glycoprotein I deficiency and the risk of thrombosis
35. 2-glycoprotein I null mice
36. Antiphospholipid antibodies and infertility
37. 2-glycoprotein I
38. Protein C and other cofactors involved in the binding of antiphospholipid antibodies. Relation to the pathogenesis of thrombosis
39. 2-GPI): A possible mechanism in the inhibitory effect of antiphospholipid antibodies on the protein C system
40. Autoantibodies to heparin from patients with antiphospholipid antibody syndrome inhibit formation of antithrombin III-thrombin complexes
41. The clonal analysis of anticardiolipin antibodies in a single patient with primary antiphospholipid syndrome reveals an extreme antibody heterogeneity
42. The role of oxidized LDL in atherogenesis: Immunological response and anti-phospholipid antibodies
43. 2 glycoprotein I (and other proteins)
44. Affinity-purified cardiolipin-binding antibodies show heterogeneity in their binding to oxidized low-density lipoprotein
45. Autoantibodies against oxidized low-density lipoprotein in antiphospholipid syndrome
46. 2 GPI
47. Immunization with anticardiolipin cofactor (β-2-glycoprotein I) induces experimental antiphospholipid syndrome in naive mice
48. In vivo models of thrombosis for the antiphospholipid syndrome
49. Effect of human IgG antiphospholipid antibodies on an in vivo thrombosis model in mice
50. A monoclonal IgG anticardiolipin antibody from a patient with the antiphospholipid syndrome is thrombogenic in mice
51. Atherosclerosis in LDL-receptor knockout mice is accelerated by immunization with anticardiolipin antibodies
52. 2-glycoprotein I). Report on the gene structure, a common polymorphism, and a high prevalence of antiphospholipid antibodies
53. Protein terminology tangle
54. "Annexinopathies" - A new class of disease
55. Distinct annexin subfamilies in plants and protists diverged prior to animal annexins and from a common ancestor
56. Displacement of factor Va by annexin V
57. Sub-domain structure of lipid-bound annexin-V resolved by electron image analysis
58. Three-dimensional structure of membrane-bound annexin V: A correlative electron microscopy-X-ray crystallography study
59. Surface topography of the p3 and p6 annexin V crystal forms determined by atomic force microscopy
60. Annexin V-heparin oligosaccharide complex suggests heparan sulfate-mediated assembly on cell surfaces
61. The expression of the placental anticoagulant protein, annexin V, by villous trophoblasts: Immunolocalization and in vitro regulation
62. Monoclonal antiphospholipid antibody reactivity against human placental trophoblast
63. Pregnancy loss in the antiphospholipid-antibody syndrome - A possible thrombogenic mechanism
64. Annexin V is critical in the maintenance of murine placental integrity
65. Placental anticoagulant protein-I: Measurement in extracellular fluids and cells of the hemostatic system
66. Immunohistochemical study of annexin V expression in placentae of preeclampsia
67. Reduction of annexin-V (placental anticoagulant protein-I) on placental villi of women with antiphospholipid antibodies and recurrent spontaneous abortion
68. Antiphospholipid immunoglobulin G antibodies reduce annexin-V levels on syncytiotrophoblast apical membranes and in culture media of placental villi
69. Antiphosphatidylserine antibody removes annexin-V and facilitates the binding of prothrombin at the surface of a choriocarcinoma model of trophoblast differentiation
70. Antiphospholipid antibodies accelerate plasma coagulation by inhibiting annexin-V binding to phospholipids: A "lupus procoagulant" phenomenon
71. A possible solution to the paradox of the "lupus anticoagulant": Antiphospholipid antibodies accelerate thrombin generation by inhibiting annexin-V
72. Antiphospholipid antibodies reduce annexin-V and accelerate coagulation on cell membranes: Mechanistic studies with a monoclonal antiphospholipid antibody
73. Human monoclonal antiphospholipid antibodies displace annexin-V from phospholipid bilayers and accelerate thrombin generation
74. 2-glycoprotein I (GPI) autoantibodies, annexin V binding and the anti-phospholipid syndrome
75. Competition of annexin V and anticardiolipin antibodies for binding to phosphatidylserine containing membranes
76. No evidence for enhanced thrombin formation through displacement of annexin V by antiphospholipid antibodies
77. Complexes of anti-prothrombin antibodies and prothrombin cause lupus anticoagulant activity by competing with the binding of clotting factors for catalytic phospholipid surfaces
78. Possible pathogenetic role of activated platelets in the primary antiphospholipid syndrome involving the central nervous system
79. Comparison of the effects of anticardiolipin antibodies from patients with the antiphospholipid syndrome and with syphilis on platelet activation and aggregation
80. Platelet activation induced by combined effects of anticardiolipin and lupus anticoagulant IgG antibodies in patients with systemic lupus erythematosus - Possible association with thrombotic and thrombocytopenic complications
81. Thromboagglutination by anticardiolipin antibody complex in the antiphospholipid syndrome, a possible mechanism of immune-mediated thrombosis
82. Imbalance of thromboxane/prostacyclin biosynthesis in patients with lupus anticoagulant
83. Thrombosis associated with antiphospholipid antibodies cannot be explained by effects on endothelial and platelet prostanoid synthesis
84. Do some antiphospholipid antibodies target endothelial cells?
85. Anti-endothelial cell antibodies to the endothelial hybridoma cell line (EAhy926) in systemic lupus erythematosus patients with antiphospholipid antibodies
86. 2-glycoprotein I in the antiphospholipid syndrome: Prevalence and isotype distribution
87. Activation of cultured vascular endothelial cells by antiphospholipid antibodies
88. Endothelial activation by aPL: A potential pathogenetic mechanism for the clinical manifestations of the syndrome
89. Thrombogenic effects of antiphospholipid antibodies are mediated by intercellular cell adhesion molecule-1, vascular cell adhesion molecule-1, and P-selectin
90. Functional analyses of patient-derived IgG monoclonal anticardiolipin antibodies using in vivo thrombosis and in vivo microcirculation models
91. Induction of endothelial cell tissue factor activity by sera from patients with antiphospholipid syndrome: A possible mechanism of thrombosis
92. Antiphospholipid antibody positive sera enhance endothelial cell procoagulant activity - Studies in a thrombosis model
93. Arterial disease and thrombosis in the antiphospholipid syndrome: A pathogenic role for endothelin 1
94. Localization of the apoptosis-inducing activity of lupus anticoagulant in an annexin V-binding antibody subset
95. In vitro generation of endothelial microparticles and possible prothrombotic activity in patients with lupus anticoagulant
96. 2-glycoprotein I antibodies and anti-endothelial cell antibodies induce tissue factor in endothelial cells
97. Antiphospholipid antibodies (aPL) increase the potential monocyte procoagulant activity in patients with systemic lupus erythematosus
98. 2-glycoprotein-I-specific T lymphocytes is associated with thrombosis and fetal loss in patients with antiphospholipid antibodies
99. Hypercoagulable state in patients with antiphospholipid syndrome is related to high induced tissue factor expression on monocytes and to low free protein s
100. Tissue factor pathway and the antiphospholipid syndrome
101. 2-glycoprotein I associated with antiphospholipid syndrome suppress the inhibitory activity of tissue factor pathway inhibitor
102. Anti-tissue factor pathway inhibitor activity in patients with primary antiphospholipid syndrome
103. The anticoagulant and anti-inflammatory roles of the protein C anticoagulant pathway
104. Protein C and other cofactors involved in the binding of antiphospholipid antibodies: Relation to the pathogenesis of thrombosis
105. Antiphospholipid antibodies and the protein C pathway
106. Coagulation activation and fibrinolytic imbalance in subjects with idiopathic antiphospholipid antibodies - A crucial role for acquired free protein S deficiency
107. Free protein S deficiency may be found in patients with antiphospholipid antibodies who do not have systemic lupus erythematosus
108. Antiphospholipid antibodies are directed against epitopes of oxidized phospholipids: Recognition of cardiolipin by monoclonal antibodies to epitopes of oxidized low density lipoprotein
109. Antiphospholipid antibodies and atherosclerosis
110. 2-glycoprotein I